Affordable Access

Access to the full text

There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF)

Authors
  • Nambiar, Shabarinath1
  • Clynick, Britt2, 3
  • How, Bong S.1, 1
  • King, Adam4
  • Walters, E. Haydn5, 6, 7, 8
  • Goh, Nicole S.9, 10
  • Corte, Tamera J.11, 12
  • Trengove, Robert1, 1
  • Tan, Dino2, 3
  • Moodley, Yuben2, 3, 13
  • 1 Murdoch University, Murdoch, WA, Australia , Murdoch (Australia)
  • 2 University of Western Australia, Crawley, WA, Australia , Crawley (Australia)
  • 3 Institute for Respiratory Health, Nedlands, WA, Australia , Nedlands (Australia)
  • 4 Waters Corporation, Stamford Avenue, Wilmslow, SK9 4AX, UK , Wilmslow (United Kingdom)
  • 5 Alfred Hospital, Melbourne, VIC, Australia , Melbourne (Australia)
  • 6 University of Tasmania, Hobart, TAS, Australia , Hobart (Australia)
  • 7 University of Melbourne, Parkville, VIC, Australia , Parkville (Australia)
  • 8 Royal Hobart Hospital, Hobart, TAS, Australia , Hobart (Australia)
  • 9 Austin Hospital, Heidelberg, VIC, Australia , Heidelberg (Australia)
  • 10 Institute of Breathing and Sleep, Heidelberg, VIC, Australia , Heidelberg (Australia)
  • 11 University of Sydney, Camperdown, NSW, Australia , Camperdown (Australia)
  • 12 Royal Prince Alfred Hospital, Camperdown, NSW, Australia , Camperdown (Australia)
  • 13 Fiona Stanley Hospital, Murdoch, WA, Australia , Murdoch (Australia)
Type
Published Article
Journal
Respiratory Research
Publisher
BioMed Central
Publication Date
Apr 09, 2021
Volume
22
Issue
1
Identifiers
DOI: 10.1186/s12931-021-01682-3
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by fibrosis and progressive loss of lung function. The pathophysiological pathways involved in IPF are not well understood. Abnormal lipid metabolism has been described in various other chronic lung diseases including asthma and chronic obstructive pulmonary disease (COPD). However, its potential role in IPF pathogenesis remains unclear.MethodsIn this study, we used ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) to characterize lipid changes in plasma derived from IPF patients with stable and progressive disease. We further applied a data-independent acquisition (DIA) technique called SONAR, to improve the specificity of lipid identification.ResultsStatistical modelling showed variable discrimination between the stable and progressive subjects, revealing differences in the detection of triglycerides (TG) and phosphatidylcholines (PC) between progressors and stable IPF groups, which was further confirmed by mass spectrometry imaging (MSI) in IPF tissue.ConclusionThis is the first study to characterise lipid metabolism between stable and progressive IPF, with results suggesting disparities in the circulating lipidome with disease progression.

Report this publication

Statistics

Seen <100 times